Glue composition for lung volume reduction

• US RE47,231 E1
• Filed: 09/27/2016
• Issued: 02/12/2019
• Est. Priority Date: 06/16/2004
• Status: Active Grant

• Current Assignee: EKOS Corporation (Boston Scientific Corporation)
• Original Assignee: PneumRx, Inc. (Boston Scientific Corporation)
• Inventors: Gong, Glen, Dieck, Ronald
• Primary Examiner(s): Kugel, Timothy J.
• Application Number:
  US15/277,826
• Time in Patent Office: 868 Days
• Field of Search: 514200
• CPC Class Codes: A61K 38/55 Protease inhibitors
• CPC Class Codes: A61K 38/57 from animals; from humans A61K38/553, A61K38/556 take precedence
• CPC Class Codes: A61K 47/6425 the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
• CPC Class Codes: A61K 47/66 the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
• CPC Class Codes: A61K 51/088 conjugates with carriers being peptides, polyamino acids or proteins antibodies A61K51/10
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

The present invention relates to methods and compositions for sealing localized regions of damaged lung tissue to reduce overall lung volume. The glue compositions provide a glue featuring an adhering moiety coupled to one or more other moieties including, for example, a cross-linkable moiety and/or one other adhering moiety. The methods and compositions of the invention find use, for example, in treating pulmonary conditions, such as emphysema.

Claims

1. A method of reducing lung volume in a lung of a subject in need thereof, comprising:

administering an effective amount of a glue composition to a localized region of damaged lung tissue of the subject, wherein the glue composition comprises a polyvinylalcohol polymer and a cross-linker, such that the polymer and cross-linker form a hydrogel in the lung, thereby reducing lung volume in the lung of the subject.

2. The method of claim 1, wherein said lung tissue comprises epithelial lining fluid.

3. The method of claim 1, wherein said administering delivers said glue composition to a deep lung region.

4. The method of claim 1, wherein said method is performed with prior identification of said damaged lung tissue.

5. The method of claim 1, wherein said glue composition further comprises a sclerosing agent that damages epithelial cells within lung tissue.

6. The method of claim 5, wherein said sclerosing agent is at least one compound selected from doxycycline, bleomycin, minocycline, doxorubicin, cisplatin+cytarabine, mitoxantrone, Corynebacterium Parvum, streptokinase, and urokinase.

7. The method of claim 1, wherein said glue composition is less than 10 microns.

8. The method of claim 1, wherein said glue composition is less than 5 microns.

9. The method of claim 1, wherein said glue composition is less than 1 micron.

10. The method of claim 1, wherein said administering is carried out via inhalation.

11. The method of claim 10, wherein said inhalation is carried out via the mouth.

12. The method of claim 1, wherein said administering is carried out via trans-thoracic administration.

13. The method of claim 1, wherein said administering is carried out by placing a bronchoscope in a bronchi of a deep lung region.

14. The method of claim 13, further comprising placing a catheter through said bronchoscope to reach a subsegmental bronchi.

15. The method of claim 14, wherein said catheter comprises an expandable balloon-like structure.

16. The method of claim 1, wherein said subject is suffering from a pulmonary condition.

17. The method of claim 16, wherein said pulmonary condition is emphysema or chronic obstructive pulmonary disease.

18. A method of reducing lung volume in a lung of a subject in need thereof comprising:

providing a glue composition comprising a cross-linkable moiety and a polyvinylalcohol;

administering said glue composition to a localized region of the lung tissue of the subject; and

cross-linking said cross-linkable moiety and said polyvinylalcohol to form a hydrogel, thereby reducing lung volume.

19. The method of claim 18, wherein said glue composition further comprises a sclerosing agent that damages epithelial cells within lung tissue.

20. The method of claim 19, wherein said sclerosing agent is at least one compound selected from doxycycline, bleomycin, minocycline, doxorubicin, cisplatin+cytarabine, mitoxantrone, Corynebacterium Parvum, streptokinase, and urokinase.

21. A glue composition comprising:

a polymer;

a cross-linker, such that the polymer and cross-linker form a hydrogel; and

a sclerosing agent.

22. The glue composition of claim 21, wherein the polymer is a polyalcohol.

23. The glue composition of claim 21, wherein the polymer is polyvinylalcohol.

24. The glue composition of claim 21, wherein the cross-linker is glutaraldehyde.

25. The glue composition of claim 21, wherein said sclerosing agent is at least one compound selected from doxycycline, bleomycin, minocycline, doxorubicin, cisplatin+cytarabine, mitoxantrone, Corynebacterium Parvum, streptokinase, and urokinase.

26. The glue composition of claim 21, wherein said glue composition is less than 10 microns.

27. The glue composition of claim 21, wherein said glue composition is less than 5 microns.

28. The glue composition of claim 21, wherein said glue composition is less than 1 micron.

29. A glue composition comprising:

a cross-linkable moiety; and

a polyalcohol, such that said cross-linkable moiety and said polyalcohol form a hydrogel; and

a sclerosing agent.

30. The glue composition of claim 29, wherein said sclerosing agent is at least one compound selected from doxycycline, bleomycin, minocycline, doxorubicin, cisplatin+cytarabine, mitoxantrone, Corynebacterium Parvum, streptokinase, and urokinase.

31. A system for reducing lung volume in a lung of a patient, the system comprising:

a delivery catheter advanceable through a bronchoscope in an airway of the lung of the patient to a localized treatment site of damaged lung tissue; and

a glue composition injectable through the delivery catheter to the localized treatment site, wherein the glue composition comprises a polyvinylalcohol polymer and a cross-linker, such that the polymer and cross-linker form a hydrogel in the lung upon administration, thereby reducing lung volume in the lung of the patient.

32. The system of claim 31, wherein said catheter comprises an expandable balloon-like structure.

33. The system of claim 31, wherein the cross-linker is glutaraldehyde.

34. The system of claim 31, wherein said glue composition further comprises a sclerosing agent that damages epithelial cells within lung tissue.

35. The system of claim 34, wherein said sclerosing agent is at least one compound selected from doxycycline, bleomycin, minocycline, doxorubicin, cisplatin+cytarabine, mitoxantrone, Corynebacterium Parvum, streptokinase, and urokinase.

36. The system of claim 31, wherein said glue composition is less than 10 microns.

37. The system of claim 31, wherein said glue composition is less than 5 microns.

38. The system of claim 31, wherein said glue composition is less than 1 micron.

39. The system of claim 31, wherein said patient is suffering from a pulmonary condition.

40. The system of claim 39, wherein said pulmonary condition is emphysema or chronic obstructive pulmonary disease.